autoscoRA: Deep Learning to Automate Sharp/van der Heijde Scoring of Radiographic Damage in Rheumatoid Arthritis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

autoscoRA: Utilizing Deep Learning for Automated Scoring of Radiographic Damage in Rheumatoid Arthritis According to Sharp/van der Heijde Criteria

  • By

  • Thomas Deimel

  • Paul J. Weiser

  • Martin Urschler

  • Christian Payer

  • Peter Mandl

  • Georg Langs

  • Daniel Aletaha

  • May 20, 2026

Share

  • 1

    Rheumatoid arthritis (RA) is characterized by chronic inflammation leading to joint damage, necessitating regular imaging for assessment.

  • 2

    The Sharp/van der Heijde (SvdH) score is a widely used tool for quantifying structural joint damage in RA but is time-consuming and requires expert interpretation.

  • 3

    Automated scoring systems, like autoscoRA, aim to improve the reliability and feasibility of assessing radiographic damage in RA.

  • 4

    Deep learning advancements have made automated scoring of radiographic damage more achievable, addressing limitations of previous systems.

  • 5

    The study utilized a large dataset of RA patients to develop and validate the autoscoRA model for automated scoring of radiographs.

Original Source(s)

autoscoRA: Deep Learning to Automate Sharp/van der Heijde Scoring of Radiographic Damage in Rheumatoid Arthritis

  • by Thomas Deimel, Paul J. Weiser, Martin Urschler, Christian Payer, Peter Mandl, Georg Langs, Daniel Aletaha

  • May 20, 2026

Related Content

RA Genetics May Reveal Link to Gum Disease

Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.